Submission of Declaration of Conformity for CE mark for Avacta’s rapid antigen test
Avacta Group PLC (AVCT.L) AffiDX SARS-CoV-2 Antigen Lateral Flow Test Update
Avacta Group PLC (AVCT.L) Final Results
Preliminary Results for the year ending 31 December 2020
Avacta Group PLC (AVCT.L) Clinical validation of AffiDX ® SARS-CoV-2 Antigen Lateral Flow Test
98.0% clinical sensitivity for samples with PCR Ct values [1] up to 31
Avacta Group PLC (AVCT.L) Directorate Change
Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the Dr Mike Owen has stepped down
Joshua Fegan, CEO & Managing Director of Althea Group Hldgs. (AGH.ASX) Interview
Althea releases new investor presentation detailing European expansion and strategic growth plan
Althea Group Hldgs. (AGH.ASX) European expansion and strategic growth plan
Althea releases new investor presentation detailing European expansion and strategic growth plan
Avacta Group PLC (AVCT.L) Rapid Antigen Test Detects SARS-CoV-2 Variants
Avacta’s AffiDX® SARS-CoV-2 lateral flow test detects both B117 ‘Kent’ and D614G variants of the virus
Avacta Group PLC (AVCT.L) Significant momentum in both Diagnostics and Therapeutics Divisions
AffiDX®, SARS-CoV-2 Lateral Flow Rapid Antigen Test generates excellent initial clinical sensitivity and specificity data MHRA approves Clinical Trial Authorisation of first therapeutic product candidate
Avacta Group PLC (AVCT.L) Re: Press Speculation
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, notes the recent press speculation about UK Government take-up of Avacta’s lateral flow SARS-CoV-2 rapid antigen test.
MGC Pharmaceuticals (MXC.ASX.L) Signs a landmark Master Supply & Distribution agreement
Master Supply & Distribution agreement signed with Swiss PharmaCan AG for exclusive worldwide[1] distribution of ArtemiCTM Rescue
Avacta Group PLC (AVCT.L) Commercial Partnership with Mologic
Partnership to accelerate CE marking of Avacta’s SARS-CoV-2 rapid antigen test and support COVID-19 testing in low and middle income countries
